Source: The Lancet Child & Adolescent Health
Authors: Prof Ravi Savarirayan, MD • Prof William R Wilcox, MD • Prof Paul Harmatz, MD • John Phillips III, MD • Lynda E Polgreen, MD • Louise Tofts, MBBS • Prof Keiichi Ozono, MD • Paul Arundel, MBBS • Melita Irving, MD • Prof Carlos A Bacino, MD • Donald Basel, MBChB • Prof Michael B Bober, MD • Prof Joel Charrow, MD • Hiroshi Mochizuki, MD • Yumiko Kotani, MD • Howard M Saal, MD • Clare Army, BSc • George Jeha, MD • Yulan Qi, PhD • Lynn Han, PhD • Elena Fisheleva, MD • Alice Huntsman-Labed, PhD • Jonathan Day, MBBS
Published: November 17, 2023 • DOI: https://doi.org/10.1016/S2352-4642(23)00265-1
Summary
Background
Vosoritide is a recombinant C-type natriuretic peptide analogue that increases annualised growth velocity in children with achondroplasia aged 5–18 years. We aimed to assess the safety and efficacy of vosoritide in infants and children younger than 5 years.
Methods
This double-blind, randomised, placebo-controlled, phase 2 trial was done in 16 hospitals across Australia, Japan, the UK, and the USA. Children younger than 60 months with a clinical diagnosis of achondroplasia confirmed by genetic testing and who had completed a baseline growth study or observation period were enrolled into one of three sequential cohorts based on age at screening: 24–59 months (cohort 1); 6–23 months (cohort 2); and 0–5 months (cohort 3). Each cohort included sentinels who received vosoritide to determine appropriate daily drug dose, with the remainder randomly assigned (1:1) within each age stratum (except in Japan, where participants were randomly assigned within each cohort) to receive daily subcutaneous injections of vosoritide (30·0 ?g/kg for infants aged 0–23 months; 15·0 ?g/kg for children aged 24–59 months) or placebo for 52 weeks. Participants, caregivers, investigators, and the sponsor were masked to treatment assignment. The first primary outcome was safety and tolerability, assessed in all participants who received at least one study dose. The second primary outcome was change in height Z score at 52 weeks from baseline, analysed in all randomly assigned participants. This trial is registered with EudraCT, 2016-003826-18, and ClinicalTrials.gov, NCT03583697.
Findings
Between May 13, 2018, and March 1, 2021, 75 participants were recruited (37 [49%] females). 11 were assigned as sentinels, whereas 32 were randomly assigned to receive vosoritide and 32 placebo. Two participants discontinued treatment and the study: one in the vosoritide group (death) and one in the placebo group (withdrawal). Adverse events occurred in all 75 (100%) participants (annual rate 204·5 adverse events per patient in the vosoritide group and 73·6 per patient in the placebo group), most of which were transient injection-site reactions and injection-site erythema. Serious adverse events occurred in three (7%) participants in the vosoritide group (decreased oxygen saturation, respiratory syncytial virus bronchiolitis and sudden infant death syndrome, and pneumonia) and six (19%) participants in the placebo group (petit mal epilepsy, autism, gastroenteritis, vomiting and parainfluenza virus infection, respiratory distress, and skull fracture and otitis media). The least-squares mean difference for change from baseline in height Z score between the vosoritide and placebo groups was 0·25 (95% CI ?0·02 to 0·53).
Interpretation
Children with achondroplasia aged 3?59 months receiving vosoritide for 52 weeks had a mild adverse event profile and gain in the change in height Z score from baseline.
Funding
- Savarirayan R • Ireland P • Irving M • et al.
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia.
Nat Rev Endocrinol. 2022; 18: 173-189 - Harada D • Namba N • Hanioka Y • et al.
Final adult height in long-term growth hormone-treated achondroplasia patients.
Eur J Pediatr. 2017; 176: 873-879 - Savarirayan R • Tofts L • Irving M • et al.
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Lancet. 2020; 396: 684-692 - Savarirayan R • Irving M • Bacino CA • et al.
C-type natriuretic peptide analogue therapy in children with achondroplasia.
N Engl J Med. 2019; 381: 25-35 - Hoover-Fong JE • Schulze KJ • McGready J • Barnes H • Scott CI
Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height.
Am J Clin Nutr. 2008; 88: 364-371 - Pauli RM • Scott CI • Wassman Jr, ER • et al.
Apnea and sudden unexpected death in infants with achondroplasia.
J Pediatr. 1984; 104: 342-348 - Hashmi SS • Gamble C • Hoover-Fong J • et al.
Multicenter study of mortality in achondroplasia.
Am J Med Genet A. 2018; 176: 2359-2364 - Coghlan RF • Oberdorf JA • Sienko S • et al.
A degradation fragment of type X collagen is a real-time marker for bone growth velocity.
Sci Transl Med. 2017; 9eaan4669 - National Center for Health Statistics
Growth charts: United States.
https://www.cdc.gov/growthcharts/index.htm
Date: 2010
Date accessed: October 25, 2021 - Centers for Disease Control and Prevention
National Center for Health Statistics. Clinical Growth Charts.
https://www.cdc.gov/growthcharts/clinical_charts.htm
Date accessed: January 24, 2022 - Hecht JT • Nelson FW • Butler IJ • et al.
Computerized tomography of the foramen magnum: achondroplastic values compared to normal standards.
Am J Med Genet. 1985; 20: 355-360 - Hoover-Fong J • Cheung MS • Fano V • et al.
Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history.
Bone. 2021; 146115872 - Lorget F • Kaci N • Peng J • et al.
Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Am J Hum Genet. 2012; 91: 1108-1114 - Yamanaka S • Nakao K • Koyama N • et al.
Circulatory CNP rescues craniofacial hypoplasia in achondroplasia.
J Dent Res. 2017; 96: 1526-1534 - Savarirayan R • Irving M • Maixner W • et al.
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Sci Prog. 2021; 104 (368504211003782) - Hecht JT • Horton WA • Reid CS • Pyeritz RE • Chakraborty R
Growth of the foramen magnum in achondroplasia.
Am J Med Genet. 1989; 32: 528-535 - Savarirayan R
Emerging drug targets for achondroplasia.
Expert Opin Ther Targets. 2022; 26: 389-391